Officials said the site was closed “due to a plethora of caution” after some people had side effects to the Johnson & Johnson / Janssen shots.
DENVER, Colorado – Vaccinated people have been diverted from a mass vaccination site at Dick Sporting Goods Park after some Johnson & Johnson vaccine recipients on the spot had an adverse reaction, according to a Centura Health spokesman.
Of the more than 1,700 people who received vaccinations on the site on Wednesday, Centura Health said 0.8% ̵
Officials said the meetings were postponed for the rest of the day as a precautionary measure as they investigated.
“Following the administration of the J&J vaccine and during on-site monitoring, we saw a limited number of adverse reactions to the vaccine,” a statement from Centura Health said.
About 640 patients were rejected and will be automatically reassigned to another vaccine clinic on Sunday, April 11, Centura Health reported.
> Video above March 28: Some experience a 3-hour wait at a mass vaccination site in Colorado.
RELATED: Some experience a 3-hour wait at a mass vaccination site in Denver on Sunday
During its first weekend of surgery, which began on March 27, the Commerce City mass vaccination site experienced long lines of cars and frustrated people.
Some told 9NEWS they waited in line for three hours this Sunday at a mass vaccination site in Dick Sporting Goods Park.
Those who have registered to receive the vaccine on the spot are told to wait 15 to 30 minutes.
Centura Health, which runs the site, told 9NEWS that its partner, COVIDCheck, Colorado, “failed to provide enough staff to respond to escalating vaccine volumes.”
“[COVIDCheck Colorado] have adjusted their resources and are working quickly to improve waiting times, “a statement from Centura Health said. Centura is committed to following all vaccines and will not refuse anyone who has planned to receive their first dose.
RELATED: Emergent BioSolutions, a Maryland-based company that had to dispose of 15M J&J vaccines, had a history of the disorder
Johnson & Johnson said Wednesday that a batch of vaccine made by Emergent BioSolutions at its Baltimore plant, known as Bayview, could not be used because it did not meet quality standards. It was not clear how the problem would affect future deliveries of the J&J vaccine. The company said in a statement that it still plans to deliver 100 million doses by the end of June and “aims to deliver those doses by the end of May.”
The company at the heart of the quality problems, which led Johnson & Johnson to dispose of 15 million doses of its coronavirus vaccine, has a number of quotes from US health officials about quality control problems.
Emergent BioSolutions, a little-known company vital to the vaccine supply chain, was key to Johnson & Johnson’s plan to deliver 100 million doses of its single vaccine to the United States by the end of May. But the Food and Drug Administration has repeatedly cited Emergent of problems such as poorly trained employees, cracked vials and problems managing mold and other contaminants around one of its facilities, according to records obtained by the Associated Press through the Freedom of Information Act. in emergency facilities since 2017.
SUGGESTED VIDEO: Covid-19 vaccine